Why Did Scotiabank Give Tempest Therapeutics Inc (TPST) Stock Sector Outperform Rating?

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.


Sponsored

Tempest Therapeutics Inc (TPST) Stock Trading Recap

On Thursday, Tempest Therapeutics Inc (TPST) stock saw a decline, ending the day at $0.92 which represents a decrease of $-0.04 or -4.17% from the prior close of $0.96. The stock opened at $0.95 and touched a low of $0.9 during the day, reaching a high of $0.98. The volume of shares traded was 2.08 million falling short of the average volume of 4.62 million.

TPST Stock Performance and Moving Averages

In recent trading, Tempest Therapeutics Inc (TPST) stock price has shown some volatility, fluctuating -13.67% over the last five trades and -31.71% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -74.15%, and it has plunged by -42.08% in the previous three months. Currently, TPST is trading at -19.37%, -27.28%, and -65.24% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.

As of the latest trading close, TPST, a Healthcare sector stock, is trading -84.75% below its 52-week high but remains 3.99% above its 52-week low. The Average True Range (ATR) (14 days) of 0.13 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.

Tempest Therapeutics Inc’s Profitability and Valuation Ratios

Tempest Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -74.15%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.

In terms of valuation, Tempest Therapeutics Inc’s market capitalization stands at $24.31 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 1.32, comparing the market value to the company’s book value.

Understanding Insider Trading

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.95% of Tempest Therapeutics Inc (TPST)’s shares, while financial institutions hold 7.10%.

Related Posts